Perampanel, a selective, noncompetitive aleph-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: Interim results from phase III, extension study 307
Gregory L Krauss, Emilio Perucca, Elinor Ben-Menachem, Patrick Kwan, Jerry J Shih, David Squillacote, Haichen Yang, Michelle Gee, Jin Zhu, Antonio Laurenza
Epilepsia | WILEY-BLACKWELL | Published : 2013
This study was funded by Eisai, Inc. Editorial support was provided by Deborah McGregor, Ph.D., of Complete Medical Communications and was funded by Eisai Inc.G. L. Krauss is currently an investigator for Eisai, UCB Pharma, Neuronex, Sunovion, and NIH/NIA. He is a consultant for Eisai as a member of the Epilepsy Study Consortium. E. Perucca received research grants from the European Union, the Italian Medicines Agency, the Italian Ministry of Health, and the Italian Ministry for Education, University and Research. He also received speaker's or consultancy fees and/or research grants from Bial, Eisai, GSK, Johnson & Johnson, Novartis, Pfizer, Sepracor, SK Life Sciences Holdings, Supernus, UCB Pharma, Upsher-Smith, Valeant, and Vertex. E. Ben-Menachem is currently an investigator for Eisai and UCB Pharma, and is a consultant for UCB Pharma, Eisai, Janssen-Cilag, Biocontrol, and Lundbeck. She has received a research grant from Vastra Gotelands Region and is chief editor of Acta Neurologica Scandinavica. P. Kwan is currently an investigator for Eisai. He received research grants from the U.S. National Institutes of Health, Hong Kong Research Grants Council, Innovation and Technology Fund, and Health and Health Services Research Fund. He also received speaker's or consultancy fees and/or research grants from Eisai, Johnson&Johnson, Pfizer, and UCB Pharma.J.J. Shih is currently an investigator for Eisai. He received research grants from the U.S. National Institutes of Health, U.S. National Science Foundation, and the Mayo Clinic Foundation. In the last 5 years, he has also received research funding from Eisai, UCB Pharma, and GSK. D. Squillacote, H. Yang, J. Zhu, and A. Laurenza are employees of Eisai Inc. M. Gee is an employee of Eisai Ltd. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.